At-Home Care Program for Acute Myeloid Leukemia Induction Phase in Patients Treated with Venetoclax-Based Low-Intensity Regimens

Venetoclax combined with azacitidine (VenAza) in patients with acute myeloid leukemia (AML) presents a high incidence of cytopenias and infections during initial treatment cycles, making early management challenging. To address this, our center implemented an At-Home (AH) program during the VenAza induction phase, focusing on therapy administration, patient and caregiver education, and adverse events (AEs) management. From March 2019 to May 2022, 75 patients with newly diagnosed or relapsed/refractory AML were treated with VenAza, with the experiment comparing outcomes between a hospital-based (inpatient) cohort of 24 patients initially admitted for treatment administration and an AH cohort (n = 44). Although most patients experienced grade 3–4 cytopenia (96.9%), the incidence of serious infections and other AEs was similar between groups. The AH cohort had a significantly lower hospital readmission rate after ramp-up (29.5% vs. 84.6%, p = 0.0001) and shorter hospital stays (8 vs. 13 days, p = 0.28). AH management proved to be safe and effective, optimizing resource use and improving patient and caregiver well-being.